Quantum Biopharma (QNTM) Liabilities and Shareholders Equity (2018 - 2026)

Quantum Biopharma (QNTM) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $14.9 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity changed 0.35% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2026 stood at $55.5 million (down 16.19% YoY), and the FY2025 full-year result was $11.2 million, down 34.8% from the prior year.
• Liabilities and Shareholders Equity grew to $14.9 million in Q1 2026, from $11.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $38.4 million in Q4 2022 to a low of $11.2 million in Q4 2025.
• A 5-year average of $17.8 million and a median of $15.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity plunged 54.51% in 2023 and climbed 0.35% in 2026, its largest moves.
• Tracing QNTM's Liabilities and Shareholders Equity over 5 years: stood at $38.4 million in 2022, then sank by 54.51% to $17.5 million in 2023, then decreased by 2.03% to $17.1 million in 2024, then tumbled by 34.8% to $11.2 million in 2025, then soared by 33.74% to $14.9 million in 2026.
• Business Quant data shows QNTM's Liabilities and Shareholders Equity at $14.9 million in Q1 2026, $11.2 million in Q4 2025, and $14.2 million in Q3 2025.